Eliquis (Apixaban) Regulatory Post Marketing Surveillance in Clinical Practice for Venous Thromboembolism (VTE) Prevention

Trial Profile

Eliquis (Apixaban) Regulatory Post Marketing Surveillance in Clinical Practice for Venous Thromboembolism (VTE) Prevention

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs Apixaban (Primary)
  • Indications Venous thromboembolism
  • Focus Adverse reactions
  • Acronyms rPMS
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 05 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jan 2016 Planned End Date changed from 1 Dec 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.
    • 07 Jan 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top